Open AccessECCO consensus: Evidence-based use of 6-thioguanine therapy in Crohn's disease?
Author(s) -
Nanne K.H. de Boer,
Dirk P. van Asseldonk,
Adriaan A. van Bodegraven
Publication year - 2010
Publication title -
journal of crohn s and colitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.277
H-Index - 80
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1016/j.crohns.2010.07.005
Subject(s) - thiopurine methyltransferase , azathioprine , crohn's disease , active metabolite , medicine , pharmacology , mercaptopurine , drug , intensive care medicine , disease , pharmacokinetics
Dear Sir,With great interest, we have read the updated ECCO consensus on the treatment of Crohn's disease.1 Being highly interested in research on the clinical use of thiopurines, we feel that several additional comments may give opportunity to a more balanced, evidence-based conclusion on the discarded use of 6-thioguanine as an alternative thiopurine.Firstly, the authors state that 6-thioguanine is the active metabolite of azathioprine and mercaptopurine. The drug 6-thioguanine has no pharmacological activity itself but needs to be metabolised to exert its immunomodulatory effects. The pharmacologically active anti-inflammatory metabolites of …
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom